Multiple GLP-1 drugs linked to lower AFib risk GLP-1 receptor agonists (GLP-1-RAs) may be able to reduce a patient's risk of atrial fibrillation (AFib), according to new data presented at Heart Rhythm 2026 in Chicago
The conflicting data in some clinical studies may be explained by various factors: [1] most cohort studies lacked individual validation of fractures as primary outcomes, [2] the studies had short follow-up duration and [3] did not consider important risk factors for osteoporosis such as BMD (even though BMD is not a good method for diagnosing osteoporosis in T2DM), and [4] some studies included medications that affect fracture risk, such as corticosteroids or antidepressants
doi:10.1136/emj.16.2.84
GTRAP3-18 hinders neurite outgrowth in vitro [61], while GTRAP3-18-deficient mice showed enhanced neurogenesis in the hippocampus [62] and spatial cognitive potentiation as assessed by the Morris water maze test [60,62]
A 76-year-old diabetic woman, who had chronic constipation and laxative abuse, underwent colonoscopy and was found to have multiple colorectal adenomas and severe melanosis coli
What ships in the box Lyophilised KLOW Blend research peptide vial KLOW Blend 80mg Janoshik Analytical Certificate of Analysis specific to the production lot HPLC purity report (99%+ standard before any vial is released